RADIOSURGERY VS OBSERVATION Question:
What are the indications for stereotactic radiosurgery (SRS) treatment vs observation for patients with intracanalicular vestibular schwannomas without evidence of radiographic progression? Recommendation: Level 3: If tinnitus is not observed at presentation, it is recommended that intracanalicular vestibular schwannomas and small tumors (<2 cm) without tinnitus be observed as observation does not have a negative impact on tumor growth or hearing preservation compared to treatment. RADIOSURGERY TECHNOLOGY Question: Is there a difference in outcome based on radiosurgery equipment used: Gamma Knife (Elekta, Stockholm, Sweden) vs linear accelerator-based radiosurgery vs proton beam? Recommendation: There are no studies that compare 2 or all 3 modalities. Thus, recommendations on outcome based on modality cannot be made. RADIOSURGERY TECHNIQUE Question: Is there a difference in outcome based on the dose delivered? Recommendation: Level 3: As there is no difference in radiographic control using different doses, it is recommended that for single fraction SRS doses, <13 Gy be used to facilitate hearing preservation and minimize new onset or worsening of preexisting cranial nerve deficits. Question: Is there a difference in outcome based on the number of fractions? Recommendation: As there is no difference in radiographic control and clinical outcome using single or multiple fractions, no recommendations can be given. RADIOGRAPHIC FOLLOW-UP, RETREATMENT, AND TUMORIGENESIS AFTER RADIOSURGERY Question: What is the best time sequence for follow-up images after SRS? Recommendation: Level 3: Follow-up imaging should be obtained at intervals after SRS based on clinical indications, a patient's personal circumstances, or institutional protocols. Long-term follow-up with serial magnetic resonance imagings to evaluate for recurrence is recommended. No recommendations can be given regarding the interval of these studies. Question: Is there a role for retreatment? Recommendation: Level 3: When there has been progression of tumor after SRS, SRS can be safely and effectively performed as a retreatment. Question: What is the risk of radiation-induced malignant transformation of vestibular schwannomas treated with SRS? Recommendation: Level 3: Patients should be informed that there is minimal risk of malignant transformation of vestibular schwannomas after SRS.
NEUROFIBROMATOSIS TYPE 2 Question:
What are the indications for SRS in patients with neurofibromatosis type 2? Recommendation: Level 3: Radiosurgery is a treatment option for patients with neurofibromatosis type 2 whose vestibular schwannomas are enlarging and/or causing hearing loss.
The full guideline can be found at: https://www.cns.org/guidelines/guidelinesmanagement-patients-vestibular-schwannoma/chapter_7. [SRT] , or conventional fractionation), dose, and post-treatment follow-up is still a matter of debate. This guideline was created to provide guidance on the use of radiation therapy for these tumors based on the data present in the literature. As for most topics, the soundness and usefulness of this data varies, depending on study design and how the data were collected. The aim of this study is to generate evidence-based guidelines for the use of radiation therapy and radiosurgery for patients with VSs.
METHODS
Details of the systematic literature review are provided in the full text of this guideline (https://www.cns.org/guidelines/guidelinesmanagement-patients-vestibular-schwannoma/chapter_7) and within the methodology article (https://www.cns.org/guidelines/guidelines-man agement-patients-vestibular-schwannoma/chapter_1) of this guideline series. The task force collaborated with a medical librarian to search for articles published from January 1, 1990 to December 31, 2014. Two electronic databases, PubMed and the Cochrane Library, were searched. Strategies for searching electronic databases were constructed by the evidence-based clinical practice guideline task force members and the medical librarian using previously published search strategies to identify relevant studies. The selected studies were classified according to criteria for evidence on therapeutic effectiveness as detailed in the Joint Guidelines Committee ABBREVIATIONS: CT, computed tomography; GK, Gamma Knife; GR, Gardner-Robertson hearing scale; LINAC, linear accelerator; MRI, magnetic resonance imaging; NF2, neurofibromatosis type 2; PTA, pure tone average; SRS, stereotactic radiosurgery; SRT, stereotactic radiotherapy; VSs, vestibular schwannomas guideline development methodology (https://www.cns.org/guidelines/ guideline-procedures-policies/guideline-development-methodology).
RESULTS
The primary search identified 956 articles. Duplicates and nonEnglish studies were removed (n = 22). Abstracts were excluded based on predefined study criteria and subject relevance (n = 15). Full-text articles were excluded based on predefined study criteria and subject relevance (n = 762). In total, 137 articles met the inclusion criteria, which resulted in 6 level 3 recommendations.
CONCLUSIONS
SRS and SRT play a role in the management of patients with VS and in patients with neurofibromatosis 2 and VS. Only class III evidence studies are currently available to formulate our guidelines. National and international prospective quality registries and clinical trials are currently ongoing and such efforts have the potential to define national patterns of care in radiosurgery, with a focus toward improving health care outcomes, supporting informed decision making, and potentially lowering the cost-ofcare delivery to patients.
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This clinical systematic review and evidence-based guideline was developed by a multidisciplinary physician volunteer task force and serves as an educational tool designed to provide an accurate review of the subject matter covered. These guidelines are disseminated with the understanding that the recommendations by the authors and consultants who have collaborated in their development are not meant to replace the individualized care and treatment advice from a patient's physician(s). If medical advice or assistance is required, the services of a competent physician should be sought. The proposals contained in these guidelines may not be suitable for use in all circumstances. The choice to implement any particular recommendation contained in these guidelines must be made by a managing physician in light of the situation in each particular patient and on the basis of existing resources.
